In Vivo Models
Validated Animal Models for Confident Preclinical Decisions
From syngeneic tumour models to CNS disease paradigms, our portfolio of rigorously characterised in vivo systems gives your compound the best chance to prove its worth before the clinic.
Request a study design
A Portfolio Built Around Translational Relevance
Every model in our portfolio is selected and validated for its predictive value. We do not run experiments — we generate evidence.
Syngeneic Tumour Models
Immunocompetent mouse models (CT26, MC38, 4T1, B16-F10) for immuno-oncology programmes. Full immune compartment intact for checkpoint inhibitor and combination studies.
Request protocol →Xenograft & PDX Models
Subcutaneous and orthotopic human tumour xenografts in nude/SCID/NSG mice. Patient-derived xenograft (PDX) models available for a panel of solid tumours.
Request protocol →Transgenic & Knock-in Models
Genetically engineered mouse models (GEMMs) for target validation, resistance mechanism studies and precision oncology. Custom colony management available.
Request protocol →CNS & Neurological Models
Validated paradigms for Parkinson’s disease (6-OHDA, MPTP), Alzheimer’s (3xTg, APP/PS1), anxiety, depression and neuropathic pain. Behavioural battery included.
Request protocol →Inflammation & Autoimmunity
Acute and chronic inflammatory models: CIA, DSS-colitis, LPS-driven sepsis, contact hypersensitivity and air pouch. Cytokine profiling and histopathology as standard.
Request protocol →PK/PD & Efficacy Studies
Single and multi-dose pharmacokinetic studies across species, integrated PK/PD modelling and dose-response characterisation to support IND-enabling packages.
Request protocol →Therapeutic Focus Areas
Our scientific team carries deep disease-area expertise so model selection and endpoint design reflect the biology — not just the assay catalogue.
Oncology
Solid tumours and haematological malignancies. Mono- and combination regimens, resistance models, biomarker-stratified cohorts and survival end-points. IO-ready syngeneic platforms.
- Tumour growth inhibition (TGI)
- Kaplan-Meier survival analysis
- Immune profiling by flow cytometry
- IHC / tumour histopathology
CNS & Neurodegeneration
Mechanistic and symptomatic models with comprehensive behavioural, biochemical and neuropathological read-outs. Experience with both small molecules and biologics.
- Motor behavioural batteries (rotarod, open field)
- Cognitive endpoints (Morris water maze, NOR)
- Neuroinflammation markers
- Brain tissue PK & target engagement
Inflammation & Immunology
Acute and chronic inflammatory paradigms with multiparameter cytokine profiling, histological scoring and mechanistic biomarker panels. Suitable for small molecules and biotherapeutics.
- Clinical scoring & body weight monitoring
- Multiplex cytokine profiling (Luminex)
- Synovial / mucosal histopathology
- Immune cell phenotyping
End-Points We Deliver as Standard
All end-points are pre-specified in the protocol, reported with full statistical analysis and formatted to meet regulatory submission requirements.
Tumour & Disease Burden
Calliper and IVIS bioluminescence imaging, digital image analysis of histological sections, organ weight and macroscopic findings.
Pharmacokinetics
Plasma, tissue and CSF sampling. LC-MS/MS bioanalysis, non-compartmental analysis (NCA) and PK/PD modelling with complete concentration-time profiles.
Biomarker Profiling
Gene expression (qPCR, RNA-seq), protein quantification (ELISA, Luminex), flow cytometry immunophenotyping and IHC/IF on FFPE tissue sections.
Safety & Tolerability
Clinical observations, body weight and food consumption, haematology, clinical chemistry, urinalysis and organ histopathology. GLP conditions available.
From Brief to Report in Three Phases
A structured process that eliminates surprises and keeps your programme on schedule.
Model Selection & Protocol Design
We review your target biology, compound profile and regulatory context, then propose the most translationally relevant model system with clear scientific justification and success criteria.
GLP-Compliant Execution
Animal husbandry, dosing, sampling and in-life observations conducted under full GLP conditions. You receive real-time access to raw data and weekly status updates from the study director.
Analysis, Report & Debrief
Comprehensive statistical analysis, narrative interpretation and a regulatory-ready final report delivered within agreed timelines, followed by a dedicated scientific debrief call.
Numbers Behind Our In Vivo Expertise
Ready to Select Your Model?
Share your compound profile and therapeutic indication. Our in vivo team will propose a study design and timeline within 48 hours.
Discuss your project